| Date | Title | Description |
| 25.01.2024 | Another step toward new drugs for Parkinson’s | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with the plight of the venture capitalist, an idea for Gilead Sciences, and the ... |
| 15.02.2022 | Kallyope Secures $236M Series D Funding |
NEW YORK, NY, Kallyope today announced the closing of a $236 million Series D financing round.
>> Click here for more funding data on Kallyope
>> To export Kallyope funding data to PDF and Excel, click here
Kallyope, a le... |
| 15.02.2022 | Kallyope scores $236M, Ro scoops up $150M and more digital health fundings | Photo: Kwanchai Lerttanapunyaporn/EyeEm/Getty Images |
| 15.02.2022 | Kallyope, with ex-Merck exec at helm, skirts 'less desirable' public markets with $236M series D | When former Merck Chief Development Officer Jay Galeota joined Kallyope in August 2021, the plan was to take the gut-brain axis biotech public. But for drug developers, the stock market has taken a turn down a treacherous path.
The six-year... |
| 15.02.2022 | Kallyope Raises $236M in Series D Financing | Kallyope, Inc., a NYC-based biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, closed a $236m Series D financing.
The round was co-led by Mubadala Investment Company and The Column Group, ... |
| 14.01.2022 | Our 2021 Predictions Report Card: How Accurate Were We? | Each year we pause to reflect on what happened in the tech and VC space and share new predictions for the coming year. Last year, we shared 10 forecasts and tech trends that we expected to see in 2021, and now we’re looking back and judging... |
| 05.08.2021 | Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth | |
| 25.03.2020 | Kallyope Announces $112M Series C Round |
NEW YORK, NY, Kallyope announced a $112 million Series C financing.
>> Click here for more funding data on Kallyope
>> To export Kallyope funding data to PDF and Excel, click here
Kallyope Inc., a leading biotechnology co... |
| 25.03.2020 | Kallyope Announces $112M Series C | Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced a $112 million Series C financing. This financing will be used to advance its portfol... |
| 25.03.2020 | Gut-brain biotech Kallyope sets sights on the clinic with $112M raise | Kallyope set out in 2015 with $44 million and a mission to map out the “information highway” between the gut and the brain. Four years later, the company is gearing up to take its first program into the clinic, and it’s bagged $112 million ... |
| 25.03.2020 | Kallyope Raises $112M in Series C Financing | Kallyope Inc., a NYC-based biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, raised $112m in Series C financing.
Backers included existing investors The Column Group, Lux Capit... |
| 25.03.2020 | Gut-brain biotech Kallyope sets sights on the clinic with $112M raise | Kallyope set out in 2015 with $44 million and a mission to map out the “information highway” between the gut and the brain. Four years later, the company is gearing up to take its first program into the clinic, and it’s bagged $112 million ... |
| 17.04.2019 | As researchers pursue links between bacteria and human health, startups stand to benefit | In 2009, the National Institutes of Health launched a five-year, $150 million project to stimulate research into a new field of medicine examining the connections between the millions of bacteria living in the human gut and overall human he... |
| 05.12.2018 | Kallyope Announces $21 Million Expansion of Series B Financing | Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $21 million expansion of its previously announced Series B financing, bringing the Series B roun... |
| 05.12.2018 | Kallyope Raises $21M Expansion of Series B Financing | Kallyope Inc., a NYC-based biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, raised a $21m expansion of its previously announced Series B financing.
This brings the Series B round total to ... |
| 05.12.2018 | Kallyope Announces $21M Expansion of Series B |
NEW YORK, NY, Biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, has announced a $21M Series B expansion.
>> Click here for more funding data on Kallyope
>> To export Kallyop... |
| 22.02.2018 | Term Sheet — Thursday, February 22 | THE KING OF RIDE-HAILING
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
Recently, reports emerged that Uber has decided to sell its Southeast Asia business to ride-hailing startup, Gr... |
| 22.02.2018 | Kallyope Raises $66M Series B | Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $66 million Series B financing and significant progress in building an industry-leading research... |
| 22.02.2018 | Kallyope Raises $66M in Series B Financing | Kallyope Inc., a NYC-based biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, raised $66m in Series B financing.
Backers included Lux Capital, The Column Group, Polaris Partners, Illumina Ve... |
| 22.02.2018 | Kallyope Raises $66M |
NEW YORK, NY, Kallyope today announced a $66 million Series B financing and significant progress in building an industry-leading research program.
>> Click here for more funding data on Kallyope
>> To export Kallyope funding... |
| 22.02.2018 | Kallyope Raises $66M Series B | Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $66 million Series B financing and significant progress in building an industry-leading research... |
| 22.02.2018 | Gut-brain biotech Kallyope ramps up, bags $66M series B | Columbia University spinout Kallyope launched back in 2015 with $44 million and a mission: to understand how the gut communicates with the brain and discover therapeutic targets. Now, the biotech is building out its technology and, with ano... |
| 16.10.2017 | Illumina Ventures Founder talks about investment priorities for first $230M fund (Updated) | Illumina Ventures Founder Nicholas Naclerio responded to questions about its investment strategy and funding priorities in an email.
He said the fund invests in life science tools, clinical diagnostics, therapeutics, and other opportunities... |
| 28.02.2017 | As Lux Capital raises $400M fund, partner answers question: What areas of healthcare interest you? | Some examples of previous healthcare and life science investments include care coordinator via telehealth, Pager; Kallyope — a Lux founded and incubated biotech pioneering a new paradigm shift for the way neurological disorders are treated ... |
| 28.02.2017 | Lux Capital closes $400 million fund to back startups ‘inventing the future’ | Lux Capital’s portfolio companies sound like they ripped their product concepts from the pages of science fiction. Among these are self-driving car startup Zoox, a company gathering oceanographic data from fleets of autonomously operating b... |
| 30.11.2016 | Axial Biotherapeutics raises $19.15M to target gut-brain axis | This builds on an array of preclinical research that has shown a link between gut bacteria and neurological conditions such as autism spectrum disorders (ASD) and Parkinson’s Disease.
The field has received a lot of buzz in recent years, bu... |
| 10.12.2015 | Kallyope launches with $44M to study gut-brain connection | “There’s increasing interest also in making compounds restricted to the gut, that actually can be used to effect behavior and metabolism,” she said.
The gut is actually a well-validated target for therapeutics discover, particularly GLP-1 b... |
| 10.12.2015 | Kallyope Launches with $44M in Series A Funding | Kallyope, Inc., a New York City-based biotech company focused on harnessing the potential of the gut-brain axis, launched with $44m in Series A funding.
Backers included Polaris Partners, Lux Capital, Illumina, Inc., The Column Group, Tony ... |
| 10.12.2015 | In a win for NYC, gut-brain biotech Kallyope launches with $44M | Kallyope CEO Nancy Thornberry
New York's ambitious plans to grow a biotech hub in the heart of its world-class scientific community is being rewarded today with the unveiling of Kallyope, a startup that's being spun out of labs at Columbia ... |
| - | The Column Group Raises a $725 Million Fourth Fund | The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG IV) and its related investment vehicles totaling $725 million. With TCG IV, th... |
| - | Illumina Ventures Founder talks about investment priorities for first $230M fund (Updated) | Early stage genomics businesses are the focus of Illumina Ventures’ first fund. Launched last year as the investment arm of biotech business Illumina, the firm has raised $230 million for the first fund, according to a news release.
So far ... |
| - | As Lux Capital raises $400M fund, partner answers question: What areas of healthcare interest you? | Early stage venture capital investor Lux Capital announced via blog post that it had raised a $400 million venture fund. Roughly 30 percent to 40 percent will in some way “touch the healthcare vertical”, said Adam Goulburn, a New York-based... |
| - | Announcing Our Investment in Castor’s $12M Series A | We are excited to announce today we’re leading Castor’s $12M Series A.
When we first met the Castor team, their ambitious goal of making the world’s clinical research data machine readable and reusable immediately resonated with us. In the... |
| - | Kallyope launches with $44M to study gut-brain connection | Scientists are beginning to unravel the connection between the brain and the stomach – finding there’s mounting evidence that the state of the gut can alter the mind, mood and neurological state, and vice versa.
Hence, the launch of Kallyop... |
| - | Kallyope Raises Another $112M to Map Out the Gut-Brain Axis to Develop Therapies to Combat Obesity | 501SHARES
FacebookTwitter
Linkedin
Rising obesity rates in the United States are a major health concern in the nation with 69% of the population being overweight and 36% being obese. More alarming is the increasing prevalence of obesity in ... |
| - | Congratulating Dusan Perovic and Frances Schwiep on their Promotion to Partner | We’re excited to announce the promotion of Dusan Perovic and Frances Schwiep to Partner. Dusan and Frances have both been invaluable members of our team for the past several years, earning this recognition through their excellent work leadi... |
| - | The Path to Precision Medicine | We believe data-driven companies can create the most powerful solutions to our world’s biggest problems. We have been increasingly excited about the intersection of data science and healthcare / biology and have already made several investm... |
| - | Kallyope Announces a $66M Series B to Develop Drugs Targeting Gut-Brain Circuits | We’re excited to announce today that Two Sigma Ventures is joining Euclidean Capital, Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, and other investors in Kallyope’s $66M Series B.
When we first met Nancy, Rob, Ian, J... |
| - | Announcing Two Sigma Ventures III, Our New $288M Fund to Back Data-Driven Founders | We’re excited to announce the close of Two Sigma Ventures III, a $288M fund that we’ll use to continue backing early-stage technology companies (primarily Series A, plus Seed and Series B) pushing the boundaries of what’s possible with data... |
| - | Axial Biotherapeutics raises $19.15M to target gut-brain axis | A new therapeutic microbiome company was officially launched on Wednesday, with the help of a $19.15 million Series A financing round led by Longwood Fund and Domain Associates.
According to the company news release, Axial Biotherapeutics a... |
